Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | ITGAL | P20701 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103090 | 0.91 | ITGAL (0.40) | ACHEITGALMAPK14 | |
| SCHEMBL6531195 | 0.84 | MAPK8 (0.43) | MAPK8ACHEHDAC1PARP1GPR119 | |
| SCHEMBL4089789 | 0.80 | HRH4 (0.42) | MAPK8ACHEMAPK14 | |
| SCHEMBL4089777 | 0.80 | PLK1 (0.43) | MAPK8HDAC1PARP1MAPK14 | |
| SCHEMBL4089886 | 0.79 | ITGAL (0.40) | ITGALMAPK14 | |
| SCHEMBL6533544 | 0.79 | VCP (0.33) | ACHEITGALMAPK14 | |
| SCHEMBL6533999 | 0.79 | PLK1 (0.42) | MAPK8HDAC1PARP1 | |
| SCHEMBL4101616 | 0.78 | PARP1 (0.40) | MAPK8HDAC1PARP1GPR119 | |
| SCHEMBL4098948 | 0.78 | PARP1 (0.40) | MAPK8HDAC1PARP1GPR119 | |
| SCHEMBL4096941 | 0.78 | PARP1 (0.40) | MAPK8HDAC1PARP1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | MAPK8 1971/4885ACHE 2633/4885ITGAL 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.